Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--May 29, 2024--
Stay updated with breaking news from Greig Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--May 29, 2024--
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling...
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. and Marc Fellous, M.D. Michael Carulli promoted to Chief Financial OfficerRobert Ticktin, General Counsel, will expand responsibilities...
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the...
SAN DIEGO, Aug. 07, 2023 -- Viracta Therapeutics, Inc. , a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients...